Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Type 1 Diabetes Mellitus: early-phase trial registry
25 of 113 indexed Type 1 Diabetes Mellitus trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #113 of 28,707 conditions by registered trial count.
113 US clinical trials · 25 currently recruiting · #113 of 28,707 conditions by registered trial count
Type 1 Diabetes Mellitus: 113 US clinical trials tracked, 25 recruiting.
Type 1 Diabetes Mellitus is the subject of 113 registered US clinical trials on ClinicalTrials.gov, 25 of them currently open to new participants. 19 are in Phase 3-4 (later-stage) and 38 in Phase 1-2 (earlier-stage). The most active sponsor is University of Virginia, running 9 of these trials.
Enrollment posture brief
Registry condition type-1-diabetes-mellitus
OPEN 25 | RECR 22% | LATE 19 | EARLY 38 | RANK #113 | SPON 9
Volume-matched condition peers
Nearest open-share peer: Acne (22% recruiting · 27 trials)
Type 1 Diabetes Mellitus lists 25 open slots (22% of 113 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Type 1 Diabetes Mellitus on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Type 1 Diabetes Mellitus is recruiting below its size-band peers.
25 of 113 indexed trials (22.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Type 1 Diabetes Mellitus trials is spread across many organizations.
University of Virginia accounts for 9 of 113 trials (8%). 67 distinct sponsors appear on at least one study for this condition label.
-
Most Type 1 Diabetes Mellitus trials plan to enrol fewer than 100 people.
Median target enrolment is 48 among the 113 trials that report a genuine target (sentinel values excluded). 80 of those (70.8%) plan for fewer than 100 participants.
-
Type 1 Diabetes Mellitus research is mostly interventional.
95 interventional and 18 observational studies make up this index (84.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
113 total, page 2 of 3
Shared Medical Decision Making in Pediatric Diabetes
Nemours Children's Clinic
NCT02496156
Effectiveness Trial of an E-Health Intervention To Support Diabetes Care in Minority Youth (3Ms)
Wayne State University
NCT03168867
Tocilizumab (TCZ) in New-onset Type 1 Diabetes
National Institute of Allergy and Infectious Diseases (NIAID)
NCT02293837
CloudConnect: Predictive And Retrospective Clinical Decision Support For Chronic Disease Management
University of Virginia
NCT03676465
The International Diabetes Closed Loop (iDCL) Trial: Protocol 1
University of Virginia
NCT02985866
6-month Comparison of Morning Lantus Versus Neutral Protamine Hagedorn Insulin in Young Children With Type 1 Diabetes
Sanofi
NCT00993473
Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes
Korey Hood
NCT02734667
Efficacy of Continuous Glucose Monitoring in Subjects With Type 1 Diabetes Mellitus on Multiple Daily Injections (MDI) or Continuous Subcutaneous Insulin Infusion (CSII) Therapy
DexCom
NCT01104142
Use of Continuous Glucose Sensors by Adolescents With Inadequate Diabetic Control
Nemours Children's Clinic
NCT00945659
Nutritional Intervention to Prevent Diabetes
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NCT00333554
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A
Hanmi Pharmaceutical Company Limited
NCT01724814
New Glucose Sensor Pediatric
Medtronic Diabetes
NCT01161043
Gene Expression Profiling in Type 1 Diabetes
Children's Mercy Hospital Kansas City
NCT00330954
PROCHYMAL® (Human Adult Stem Cells) for the Treatment of Recently Diagnosed Type 1 Diabetes Mellitus (T1DM)
Mesoblast
NCT00690066
Signaling Mechanisms and Vascular Function in Patients With Diabetes Mellitus
Brigham and Women's Hospital
NCT00762671
Effect of Diabetes Mellitus on Cholesterol Metabolism
Medical College of Wisconsin
NCT00879710
A Cognitive Behavioral Therapy (CBT) Intervention to Reduce Fear of Hypoglycemia in Type 1 Diabetes
University of Illinois at Chicago
NCT03549104
The VRIF Trial: Hypoglycemia Reduction With Automated-Insulin Delivery System
University of Virginia
NCT03674281
Sleep and Glucose Regulation in Youth With Type 1 Diabetes Mellitus
University of Arizona
NCT00848822
Copeptin in Adolescent Participants With Type 1 Diabetes and Early Renal Hemodynamic Function
University of Colorado, Denver
NCT03618420
Assess the Efficacy of the Low Glucose Suspend (LGS) Feature in the MiniMed Paradigm® X54 System
Medtronic Diabetes
NCT01148862
Islet Transplantation in Type 1 Diabetes
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00434811
Diabetic Kidney Alarm (DKA) Study
University of Colorado, Denver
NCT03128229
TAK-329 Glucose Clamp Study
Takeda
NCT01311076
Glycemic Profiles And Insulin Delivery Across The Menstrual Cycle In Women With Type 1 Diabetes
University of Virginia
NCT04665999
Medtronic Minimed Overnight Closed-Loop System
Bruce A. Buckingham
NCT01881009
Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus
Lexicon Pharmaceuticals
NCT01742208
Crossover Feasibility Study of Portable AP Device With Zone-MPC and HMS and Adapted I:C and Basal Insulin
Sansum Diabetes Research Institute
NCT01929798
The Insulin-Only Bionic Pancreas Bridging Study
Massachusetts General Hospital
NCT03565666
Tissue-Specific Metabolic Reprogramming in Diabetic Complications
University of Michigan
NCT01823406
Verapamil for Beta Cell Survival Therapy in Type 1 Diabetes
University of Alabama at Birmingham
NCT02372253
At Home Study of a Zone-Model Predictive Control (MPC) Controller and a Health Monitoring System (HMS) With the Diabetes Assistant (DiAs) System and Run-to-Run Adaptation
Sansum Diabetes Research Institute
NCT02705053
Reducing Risks and Improving Glucose Control During Extended Exercise in Youth With T1DM: The AP Ski Camp
Daniel Chernavvsky, MD, CRC
NCT02604524
Adaptive Biobehavioral Control (ABC) of Automated Insulin Delivery
University of Virginia
NCT04784637
Hyaluronidase Effect on Infusion Set Life
Stanford University
NCT02199028
Intervention Groups for Adolescents With Type 1 Diabetes Mellitus
Children's Hospital and Health System Foundation, Wisconsin
NCT00622271
Neuropsychological and Neuroanatomical Studies of Young Children With and Without Type 1 Diabetes Mellitus
Stanford University
NCT00449891
A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM)
Eli Lilly and Company
NCT03367390
Pediatric Diabetics Type 1 Using InsuPatch
Insuline Medical
NCT01368978
Effect of Ethanol Intoxication on the Anti-Hypoglycemic Action of Glucagon
Massachusetts General Hospital
NCT02516150
Glucagon Rescue of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes Treated With Volagidemab
REMD Biotherapeutics
NCT06272695
Pregnancy Intervention With a Closed-Loop System (PICLS) Study
University of Colorado, Denver
NCT03774186
Efficacy of Islet After Kidney Transplantation
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00468117
Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Using Total Daily Insulin
University of Virginia
NCT03804983
Outpatient Control-to-Range: System and Monitoring Testing
University of Virginia
NCT01578980
The Multi-Sensor Distance Accuracy Study
Oregon Health and Science University
NCT02241993
To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy
Biodel
NCT01110746
A Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Doses of SAR438544 in Comparison to Placebo and Glucagon in Healthy Subjects and Type 1 Diabetes Mellitus Patients
Sanofi
NCT02625636
Internet-Based Cognitive Behavioral Therapy for Depressive Symptoms in Adolescents With Type 1 Diabetes Mellitus
University of Texas Southwestern Medical Center
NCT03655067
Detemir: Role in Type 1 Diabetes
Montefiore Medical Center
NCT00564395
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 20 |
| Phase 2 | 18 |
| Phase 3 | 14 |
| Phase 4 | 5 |
Top Sponsors
Named interventions
Most-linked intervention names on Type 1 Diabetes Mellitus records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Type 1 Diabetes Mellitus trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Type 1 Diabetes Mellitus page
113 registered trials, 25 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 25 Type 1 Diabetes Mellitus trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- University of Virginia sponsors the most Type 1 Diabetes Mellitus trials on record, review their full trial history before evaluating a specific study. See University of Virginia's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Type 1 Diabetes Mellitus condition card totals 113 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.